The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

cyberheartinc.com

Total Raised

$14.77M

Investors Count

7

Deal Terms

3

Cyberheart Funding, Cyberheart Valuation & Cyberheart Revenue

5 Fundings

Cyberheart's latest funding round was a Acquired for on May 9, 2019.

Cyberheart's valuation in January 2008 was $20.69M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

5/9/2019

Acquired

0

FY undefined

1

2/15/2011

Unattributed VC

$99M

0

FY undefined

0

11/18/2009

Debt

$99M

0

FY undefined

0

1/10/2008

Series A

$99M

$20.69M

0

FY undefined

0

Other Investors

0

FY undefined

0

Date

5/9/2019

2/15/2011

11/18/2009

1/10/2008

Round

Acquired

Unattributed VC

Debt

Series A

Other Investors

Amount

$99M

$99M

$99M

Investors

Valuation

$20.69M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

0

0

0

0

Cyberheart Deal Terms

3 Deal Terms

Cyberheart's deal structure is available for 3 funding rounds, including their Unattributed VC from February 15, 2011.

Round

Unattributed VC

Debt

Series A

Funding Date

$99M

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

$99M

Shares Authorized

Issuance Price

$99M

$99M

Dividend Rate

$99M

$99M

Liquidation Preferences

$99M

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

$99M

General Voting

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Unattributed VC

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Debt

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

Cyberheart Investors

7 Investors

Cyberheart has 7 investors. Varian Medical Systems invested in Cyberheart's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

5/9/2019

5/9/2019

1
Acquired

Corporation

California

00/00/0000

00/00/0000

Emergent Medical Partners

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

United Investments

Subscribe to see more

Other

California

00/00/0000

00/00/0000

MC Financial Services

Subscribe to see more

Private Equity

New York

00/00/0000

00/00/0000

Alloy Ventures

Subscribe to see more

Venture Capital

California

First funding

5/9/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

5/9/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Emergent Medical Partners

United Investments

MC Financial Services

Alloy Ventures

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Venture Capital

Other

Private Equity

Venture Capital

Location

California

California

California

New York

California

You May Also Like

N
Neurosonix

NeuroSonix is an Israeli medical device company targeting the market of cerebral embolic protection during cardiac surgical and other minimally invasive procedures. NeuroSonix has conceived, developed and patented a technology and medical devices for the prevention of acute cerebral embolism during open-heart cardiac surgery as well as other invasive and minimally-invasive procedures. The company's technology, which is based on ultrasound, aims to enable a non-invasive deflection of embolic material flowing inside the body, away from the cerebral arteries. This new ultrasonic modality aims to reduce the embolic load on the patient's brain. The first product developed by the company is the EmBlocker"ž, intended to provide protection from acute cerebral embolism during cardiac surgical procedures. The Protection Collar, the company's second product, is intended for embolic protection during minimally-invasive procedures and Cath-lab practice.

O
OrSense

OrSense provides non-invasive monitoring of various blood constituencies.

I
InnerPulse

InnerPulse develops minimally invasive devices for cardiac rhythm management

A
Axis Surgical Technologies

Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment.Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.

A
Advanced Surgical Concepts

Advanced Surgical Concepts develops surgical instruments for use in endoscopy and in minimally invasive surgery

A
Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.